Clinical Study
Efficacy of Olanzapine Combined Therapy for Patients Receiving Highly Emetogenic Chemotherapy Resistant to Standard Antiemetic Therapy
Table 3
Changes of nausea grade and nausea control rate after receiving olanzapine combined with standard antiemetic therapy.
| | Acute phase (0–24 h) | Delayed phase (24–120 h) | Overall phase (0–120 h) | | Without OLN | With OLN | Without OLN | With OLN | Without OLN | With OLN |
| Nausea grade | | | | | | | 0 | 17 (34%) | 43 (86%) | 0 (0%) | 21 (42%) | 0 (0%) | 20 (40%) | 1 | 12 (24%) | 6 (12%) | 1 (2%) | 26 (52%) | 0 (0%) | 26 (52%) | 2 | 14 (28%) | 1 (2%) | 20 (40%) | 3 (6%) | 18 (36%) | 4 (8%) | 3 | 7 (14%) | 0 (0%) | 29 (58%) | 0 (0%) | 32 (64%) | 0 (0%) |
| Nausea control rate* | 58% | 98% | 2% | 94% | 0% | 92% |
| value** | | | |
|
|
OLN: olanzapine, *nausea grade 0 or 1 (CTCAE ver. 4.0), and **McNemar test.
|